Alert detail

LCD L38814: MolDX: Minimal Residual Disease Testing for Cancer — Noridian

Policy ID: LCD-L38814Specialty: OncologyAdded: 6/5/2026Effective: February 5, 2026lcd
Routine

What changed

Billing impact from new MolDX LCD for cancer tests.

Who’s affected: Oncology billing teams · Effective: February 5, 2026

Affected codes

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

This change affects 27 billing codes.

The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.